Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01346319 · ClinicalTrials.gov registry record · Phase 1

Study of the Safety, Tolerability and Pharmacokinetics of Testosterone Undecanoate in Hypogonadal Males.

A Phase 1 study of Hypogonadal Males, sponsored by Abbott.

Completed
Registry status
Phase 1
Development phase
1
Study location

NCT01346319 is a Phase 1 study of Hypogonadal Males that has completed, run by Abbott. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01346319, a Phase 1 study of Hypogonadal Males, has completed, sponsored by Abbott.

COMPLETED
Registry status
Phase 1
Development phase
1
Study location

Study Summary

Phase 1 Dose Escalating Study of the safety, tolerability and pharmacokinetics of testosterone in hypogonadal males.

Conditions Studied

Interventions

  • DRUG placebo
  • DRUG ABT-SLV361

Study Locations (1)

Florida

  • Site Reference ID/Investigator# 51964 - Fort Myers

Trial Details

FieldValue
Start Date 2011-04
Est. Completion 2011-09
Phase Phase 1

Sponsor

Abbott

181 total trials

What the Registry Record Tells You About NCT01346319

The ClinicalTrials.gov registry entry for NCT01346319 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hypogonadal Males appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT01346319 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT01346319 about?

NCT01346319 is a clinical study titled "Study of the Safety, Tolerability and Pharmacokinetics of Testosterone Undecanoate in Hypogonadal Males.". Phase 1 Dose Escalating Study of the safety, tolerability and pharmacokinetics of testosterone in hypogonadal males.

What is the current status of trial NCT01346319?

This trial is currently completed. It is a Phase 1 study. The study started on 2011-04. Estimated completion is 2011-09.

What conditions does trial NCT01346319 study?

This clinical trial studies the following conditions: Hypogonadal Males.

What interventions are being tested in trial NCT01346319?

The interventions under investigation include: placebo (DRUG), ABT-SLV361 (DRUG).

Who is sponsoring clinical trial NCT01346319?

This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01346319 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypogonadal Males

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.